Asahi Kasei reports developments across a diversified global business that includes healthcare, materials, electronic components, and hydrogen-related technologies. News commonly covers pharmaceutical pipeline expansion, specialty pharmaceutical acquisitions, antiviral and autoimmune-disease programs, and subsidiary activity involving Veloxis Pharmaceuticals, Asahi Kasei Therapeutics, and Asahi Kasei Pharma.
Company updates also include Asahi Kasei Microdevices' magnetic-sensor and photonic technology work, chlor-alkali electrolysis products such as electrolyzer cells, ion-exchange membranes, and electrodes, and Aqualyzer™ alkaline-water electrolyzer deployments for hydrogen production. Recurring themes include research collaborations, license agreements, clinical and regulatory disclosures, material agreements, capital-structure updates, and operating and financial results.
Asahi Kasei (AHKSY) announced FDA approval of its therapeutics business’s HOVILPRI tablets for treatment-resistant herpes simplex virus lesions in immunocompromised adults. The approval covers 100 mg pritelivir tablets for mucocutaneous lesions—affecting skin and mucous membranes—that do not respond to acyclovir, valacyclovir or famciclovir, with or without documented resistance.
The Phase 3 PRIOH-1 trial treated 101 adults. Complete lesion healing by Day 28 reached 63% versus 34% with Investigator’s Choice treatment, an adjusted difference of 28.4% (p=0.0047). Response rates up to Day 42 were 82% versus 42%. Adverse reactions occurred in 22% versus 54%; discontinuations due to adverse drug reactions were 2% versus 20%. Certain acid-reducing medicines can reduce exposure to pritelivir, potentially reducing effectiveness and promoting resistance. The company expects U.S. availability before the end of 2026.
Asahi Kasei (AHKSY) subsidiary Asahi Kasei Microdevices held an IEEE Milestone commemoration ceremony in Nobeoka, Japan, on October 6, 2026. The ceremony celebrated the 1983 commercialization of thin-film Hall elements, recognized by IEEE in February 2026. Hall elements detect magnetic fields and convert them into electrical signals, enabling non-contact sensing in electronic and industrial equipment.
Production has continued in Nobeoka since commercialization. Cumulative worldwide shipments of AKM Hall sensor products developed from this technology have exceeded 50 billion units.
Asahi Kasei (AHKSY) announced that its therapeutics business dosed the first patient in a Phase 2a AIC468 trial. The study evaluates the antiviral candidate in adults with BK virus infection after kidney transplantation. Aicuris Anti-infective Cures, now part of Asahi Kasei Therapeutics, developed the program.
The randomized, double-blind, placebo-controlled trial, NCT07503561, forms part of a Phase 2/3 program. It evaluates safety, tolerability and pharmacokinetics—how the body processes a drug—across multiple dose levels. The company described Phase 1 safety, tolerability and pharmacokinetic data in healthy volunteers as favorable. AIC468 is an antisense oligonucleotide, a treatment designed to act on genetic messages; it targets viral RNA processing to prevent formation of a protein essential to BK virus replication.
Asahi Kasei (AHKSY) is bringing four pharmaceutical businesses under the Asahi Kasei Therapeutics brand and a unified global management structure.
The businesses are Asahi Kasei Therapeutics in Japan, Veloxis Pharmaceuticals in the United States, Calliditas Therapeutics in Sweden and recently acquired AiCuris Anti-infective Cures in Germany. Asahi Kasei targets ¥300 billion in pharmaceutical net sales by FY2030 and plans approximately ¥40 billion of in-licensing investment over three years. It expects growth from existing products, pipeline assets, additional acquisitions and licensing.
U.S. sales of ENVARSUS XR have grown at a compound annual rate in the 20% range since the 2020 Veloxis acquisition. Asahi Kasei expects TARPEYO to continue outperforming revenue projections set at the 2024 Calliditas acquisition. AiCuris adds a royalty stream from Prevymis and potential future pipeline contributions.
Asahi Kasei (AHKSY) is introducing the VANTIJ® SU-VFC Benchtop, a compact, automated single-use virus filtration system for laboratory-scale and process development gene therapy applications, to be unveiled at Bioprocess International East 2026 in Boston.
The VANTIJ® SU-VFC Benchtop is the first benchtop platform in the VANTIJ® family and is designed for workflows using 0.12 m² or 0.3 m² Planova™ 35N virus-removal filters. It extends the automation, repeatability, and operator-focused design of existing VANTIJ® systems while simplifying small-scale Planova™ virus filtration and maintaining modern process control and data capabilities. Features include a guided shadow-board layout, tool-free tube set installation, intuitive connection points, recipe-driven software, and batch reporting to support consistent execution of critical filtration processes.
Asahi Kasei Microdevices (AHKSY) announced its CZ39 and CZ3K coreless current sensors are used in Microchip Technology’s ML/AI-based arc fault detection (AFD) reference design built around the dsPIC33A Digital Signal Controller.
The design executes signal-processing and machine-learning inference locally on the controller to improve arc fault detection versus conventional threshold methods. AKM’s sensors, featuring a 100 ns response time and low-noise signal quality, are highlighted as central to the AFD signal chain. The Microchip reference design targets applications including solar PV, energy storage systems, EV chargers, smart ignition systems, e-Fuse designs, and residential and industrial safety switches. AKM’s parent Asahi Kasei positions Electronics as a first-priority business, with current sensors described as a future growth pillar for EV, AI, and data center uses.
Asahi Kasei (OTC: AHKSY) held a grand opening on August 20 for a new Hipore™ wet-process lithium-ion battery separator coating line at its Celgard® facility in Charlotte, North Carolina. The investment adds North America-based coating and supply capacity, with commercial production planned for the second half of fiscal 2026.
The project is the first step in a regional wet-process separator supply structure, complements Celgard® dry-process output, and is aligned with a capacity rights agreement with Toyota Tsusho and a planned wet-process separator plant in Canada.
Asahi Kasei (OTC: AHKSY) has developed a novel lithium pre-doping technology for high-voltage lithium-ion batteries with silicon-based anodes. By using electrolyte additives, the process decomposes low-cost lithium carbonate at typical cell voltages, enabling it to act as a sacrificial lithium source during the first charge.
According to Asahi Kasei, internal tests on an NMC cell with a 90% graphite / 10% SiO anode showed a 10% increase in energy density. The technology is designed to improve cycle life and cost per Wh, be implemented on existing production lines, and work across various cathode/anode systems. The company plans global PoC evaluations and intends to license the technology as part of its Technology-value Business Creation initiative, targeting at least 10 new license agreements in fiscal 2025–2027 and cumulative profit contribution of ¥10 billion or more by around 2030.
Asahi Kasei (OTC: AHKSY) received regional economic incentives from Kanagawa Prefecture and the City of Kawasaki to support new facilities for alkaline water electrolysis and ion-exchange membrane chlor-alkali electrolysis equipment at its Kawasaki plant in Japan.
The company is constructing new capacity for cell frames and membranes targeting at least 2 GW each by 2028, which, combined with existing chlor-alkali capacity, is expected to lift total annual capacity to over 3 GW. According to Asahi Kasei, the Kawasaki site will be positioned as a key global hub for water electrolysis and chlor-alkali systems, underpinning a flexible supply platform for clean hydrogen and contributing to regional economic development. The project follows Japanese governmental support selected in December 2024 and formal internal approval in October 2025.
Asahi Kasei (OTC: AHKSY) signed its first non-exclusive license agreement in China with HighChem Shanghai to produce and sell Acetolyte™, an acetonitrile-containing electrolyte for lithium-ion batteries. The deal leverages HighChem Shanghai’s customer base to expand Acetolyte™ adoption and supports Asahi Kasei’s licensing-focused Technology-value Business Creation strategy, which targets at least 10 new license agreements in fiscal 2025–2027 and a cumulative profit contribution of ¥10 billion or more by around 2030.